Absence of hair from areas where it is normally present.
Loss of scalp and body hair involving microscopically inflammatory patchy areas.
The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
A tube-like invagination of the EPIDERMIS from which the hair shaft develops and into which SEBACEOUS GLANDS open. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (Stedman, 26th ed) Follicles of very long hairs extend into the subcutaneous layer of tissue under the SKIN.
A filament-like structure consisting of a shaft which projects to the surface of the SKIN from a root which is softer than the shaft and lodges in the cavity of a HAIR FOLLICLE. It is found on most surfaces of the body.
A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
Scalp dermatoses refer to various inflammatory skin conditions affecting the scalp, including seborrheic dermatitis, psoriasis, atopic dermatitis, and tinea capitis, often characterized by symptoms such as redness, scaling, itching, and hair loss.
Inflammation of follicles, primarily hair follicles.
A noninvasive technique that enables direct microscopic examination of the surface and architecture of the SKIN.
Ringworm of the scalp and associated hair mainly caused by species of MICROSPORUM; TRICHOPHYTON; and EPIDERMOPHYTON, which may occasionally involve the eyebrows and eyelashes.
Compulsion to pull out one's hair.
The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.
Abnormal sensitivity to light. This may occur as a manifestation of EYE DISEASES; MIGRAINE; SUBARACHNOID HEMORRHAGE; MENINGITIS; and other disorders. Photophobia may also occur in association with DEPRESSION and other MENTAL DISORDERS.
An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a "saw-tooth" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.
Curved rows of HAIR located on the upper edges of the eye sockets.
An insect chemosterilant and an antineoplastic agent.
Presence of less than the normal amount of hair. (Dorland, 27th ed)
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome.
Small, sacculated organs found within the DERMIS. Each gland has a single duct that emerges from a cluster of oval alveoli. Each alveolus consists of a transparent BASEMENT MEMBRANE enclosing epithelial cells. The ducts from most sebaceous glands open into a HAIR FOLLICLE, but some open on the general surface of the SKIN. Sebaceous glands secrete SEBUM.

Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. (1/646)

PURPOSE: Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent cancer of the cervix, and the combination of these two agents has shown activity and possible synergism in a variety of solid tumors. We administered this combination to patients with metastatic or recurrent cervical cancer to evaluate its activity. PATIENTS AND METHODS: Thirty-four consecutive patients were treated on an outpatient basis with paclitaxel 175 mg/m2 administered intravenously over a 3-hour period followed by cisplatin 75 mg/m2 administered intravenously with granulocyte colony-stimulating factor support. The chemotherapy was administered every 3 weeks for a maximum of six courses. RESULTS: Sixteen patients (47%; 95% confidence interval, 30% to 65%) achieved an objective response, including five complete responses and 11 partial responses. Responses occurred in 28% of patients with disease within the radiation field only and in 57% of patients with disease involving other sites. The median duration of response was 5.5 months, and the median times to progression and survival for all patients were 5 and 9 months, respectively. Grade 3 or 4 toxicities included anemia in 18% of patients and granulocytopenia in 15% of patients. Fifty-three percent of patients developed some degree of neurotoxicity; 21% of cases were grade 2 or worse. CONCLUSION: The combination of paclitaxel with cisplatin seems relatively well tolerated and moderately active in patients with metastatic or recurrent cervical cancer. The significant incidence of neurotoxicity is of concern, and alternative methods of administration of the two agents could be evaluated. Then, further study of this combination, alone or with the addition of other active agents, is warranted.  (+info)

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. (2/646)

PURPOSE: Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high response rates have been reported when it is administered in combination with cisplatin. The aim of the present study was to evaluate the combination of gemcitabine and carboplatin in a phase I-II study. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB-IV non-small-cell lung cancer received carboplatin at area under the concentration-time curve (AUC) 5 mg/mL/min and gemcitabine at an initial dose of 800 mg/m2, subsequently escalated by 100 mg/m2 per step. Gemcitabine was administered on days 1 and 8 and carboplatin on day 8 of the 28-day cycle. Dose escalation proceeded up to dose-limiting toxicity (DLT), which was defined as grade 4 neutropenia or thrombocytopenia or grade 3 nonhematologic toxicity. RESULTS: Neutropenia was DLT, inasmuch as it occurred in three of five patients receiving gemcitabine 1,200 mg/m2. Nonhematologic toxicities were mild. Gemcitabine 1,100 mg/m2 plus carboplatin AUC 5 was recommended for phase II studies. An objective response was observed in 13 (50%) of 26 patients, including four complete responses (15%) and nine partial responses (35%). Median duration of response was 13 months (range, 3 to 23 months). Median overall survival was 16 months (range, 3 to 26 months). CONCLUSION: The combination of gemcitabine and carboplatin is well tolerated and active. Neutropenia was DLT. The observed activity matches that observable in cisplatin-gemcitabine studies, whereas duration of response and survival are even higher. A phase II trial is under way.  (+info)

Longevity, stress response, and cancer in aging telomerase-deficient mice. (3/646)

Telomere maintenance is thought to play a role in signaling cellular senescence; however, a link with organismal aging processes has not been established. The telomerase null mouse provides an opportunity to understand the effects associated with critical telomere shortening at the organismal level. We studied a variety of physiological processes in an aging cohort of mTR-/- mice. Loss of telomere function did not elicit a full spectrum of classical pathophysiological symptoms of aging. However, age-dependent telomere shortening and accompanying genetic instability were associated with shortened life span as well as a reduced capacity to respond to stresses such as wound healing and hematopoietic ablation. In addition, we found an increased incidence of spontaneous malignancies. These findings demonstrate a critical role for telomere length in the overall fitness, reserve, and well being of the aging organism.  (+info)

Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. (4/646)

Leukemic patients receiving marrow from HLA-identical sibling donors were randomized to treatment with either busulfan 16 mg/kg (n = 88) or total body irradiation ([TBI] n = 79) in addition to cyclophosphamide 120 mg/kg. The patients were observed for a period of 5 to 9 years. Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =.01) and hemorrhagic cystitis (32% v 10%, P =.003). Acute graft-versus-host disease (GVHD) was similar in the two groups, but the 7-year cumulative incidence of chronic GVHD was 59% in the busulfan-treated group versus 47% in the TBI group (P =.05). Death from GVHD was more common in the busulfan group (22% v 3%, P <.001). Obstructive bronchiolitis occurred in 26% of the busulfan patients but in only 5% of the TBI patients (P <.01). Complete alopecia developed in 8 busulfan patients and partial alopecia in 17, versus five with partial alopecia in the TBI group (P <.001). Cataracts occurred in 5 busulfan-treated patients and 16 TBI patients (P =.02). The incidence of relapse after 7 years was 29% in both groups. Seven-year transplant-related mortality (TRM) in patients with early disease was 21% in the busulfan group and 12% in the TBI group. In patients with more advanced disease, the corresponding figures were 64% and 22%, respectively (P =.004). Leukemia-free survival (LFS) in patients with early disease was 68% in busulfan-treated patients and 66% in TBI patients. However, 7-year LFS in patients with more advanced disease was 17% in the busulfan group versus 49% in the TBI group (P <.01). In patients with chronic myeloid leukemia (CML) in first chronic phase, 7-year LFS was 72% and 83% in the two groups, respectively.  (+info)

Clomipramine-induced urinary retention in a cat. (5/646)

A 10-year-old, female, spayed shorthair with presumed psychogenic alopecia was treated with clomipramine (1 mg/kg body weight/day). The cat developed urinary retention within 2 days. Clomipramine was discontinued. Clinical signs resolved over the next 7 days. The urinary retention was attributed to the anticholinergic effects of clomipramine.  (+info)

Identification of a genetic defect in the hairless gene in atrichia with papular lesions: evidence for phenotypic heterogeneity among inherited atrichias. (6/646)

Recently, we showed that atrichia with papular lesions (APL), a rare inherited form of alopecia, is transmitted as an autosomal recessive trait in a large inbred kindred of Israeli-Arab origin. Furthermore, we mapped the APL locus to a 5-cM region of chromosome 8p12 in this family. The human "hairless" gene is a candidate target gene for the disease mutation because it maps to the APL locus and because it was recently found to be mutated in a related but clinically distinct form of alopecia known as "alopecia universalis" or "congenital alopecia." In the present study, the coding sequence of the hairless gene was compared by reverse transcription-PCR in fibroblast cell lines derived from an affected patient and an unrelated individual. We identified a single-base deletion (3434delC) in the hairless gene that cosegregated with the disease phenotype in the family. This deletion is predicted to cause a frameshift mutation in the highly conserved C-terminal part of the hairless protein, a region putatively involved in the transcription factor activity of the hairless gene product. The present results are indicative of phenotypic heterogeneity in inherited atrichias caused by mutations in the hairless gene, suggesting different roles for the regions mutated in APL and in other forms of congenital atrichia during hair development.  (+info)

Medical treatments for balding in men. (7/646)

Two drugs are available for the treatment of balding in men. Minoxidil, a topical product, is available without a prescription in two strengths. Finasteride is a prescription drug taken orally once daily. Both agents are modestly effective in maintaining (and sometimes regrowing) hair that is lost as a result of androgenic alopecia. The vertex of the scalp is the area that is most likely to respond to treatment, with little or no hair regrowth occurring on the anterior scalp or at the hairline. Side effects of these medications are minimal, making them suitable treatments for this benign but psychologically disruptive condition.  (+info)

Insulin gene polymorphism and premature male pattern baldness in the general population. (8/646)

Insulin is found in hair follicles and may play a role in the regulation of androgen metabolism and the hair growth cycle, which are relevant to the loss of scalp hair known as male pattern baldness. An excess of dihydrotestosterone on balding scalp indicates that the condition is androgen dependent. Premature male pattern baldness may be the male phenotype of familial polycystic ovary syndrome, a condition characterized by high levels of androgens and insulin that has been linked to insulin gene polymorphism. Therefore, we studied possible associations between relevant insulin gene polymorphisms and premature male pattern baldness in the general community. We examined the distribution of three dimorphic restriction fragment length polymorphisms: HphI, PstI and FokI in cases consisting of 56 men aged 18-30 years with significant baldness, and in 107 control men aged 50 years or more with no indication of baldness. No significant differences between cases and controls in allele, genotype or haplotype frequencies were identified. We conclude that, in the general population, the insulin gene is not associated with premature male pattern baldness.  (+info)

Alopecia is a medical term that refers to the loss of hair or baldness. It can occur in various parts of the body, but it's most commonly used to describe hair loss from the scalp. Alopecia can have several causes, including genetics, hormonal changes, medical conditions, and aging.

There are different types of alopecia, such as:

* Alopecia Areata: It is a condition that causes round patches of hair loss on the scalp or other parts of the body. The immune system attacks the hair follicles, causing the hair to fall out.
* Androgenetic Alopecia: Also known as male pattern baldness or female pattern baldness, it's a genetic condition that causes gradual hair thinning and eventual hair loss, typically following a specific pattern.
* Telogen Effluvium: It is a temporary hair loss condition caused by stress, medication, pregnancy, or other factors that can cause the hair follicles to enter a resting phase, leading to shedding and thinning of the hair.

The treatment for alopecia depends on the underlying cause. In some cases, such as with telogen effluvium, hair growth may resume without any treatment. However, other forms of alopecia may require medical intervention, including topical treatments, oral medications, or even hair transplant surgery in severe cases.

Alopecia Areata is a medical condition characterized by the sudden loss of hair in round or oval patches on the scalp or other parts of the body. It is an autoimmune disorder, which means that the immune system mistakenly attacks the hair follicles, leading to hair loss. The condition can affect both adults and children, and it can cause significant emotional distress and impact a person's quality of life. In some cases, the hair may grow back on its own, while in others, treatment may be necessary to promote hair regrowth.

The scalp is the anatomical region located at the upper part of the human head, covering the skull except for the face and the ears. It is made up of several layers: the skin, the connective tissue, the galea aponeurotica (a strong, flat, tendinous sheet), loose areolar tissue, and the periosteum (the highly vascularized innermost layer that attaches directly to the skull bones). The scalp has a rich blood supply and is home to numerous sensory receptors, including those for touch, pain, and temperature. It also contains hair follicles, sebaceous glands, and sweat glands.

A hair follicle is a part of the human skin from which hair grows. It is a complex organ that consists of several layers, including an outer root sheath, inner root sheath, and matrix. The hair follicle is located in the dermis, the second layer of the skin, and is surrounded by sebaceous glands and erector pili muscles.

The hair growth cycle includes three phases: anagen (growth phase), catagen (transitional phase), and telogen (resting phase). During the anagen phase, cells in the matrix divide rapidly to produce new hair fibers that grow out of the follicle. The hair fiber is made up of a protein called keratin, which also makes up the outer layers of the skin and nails.

Hair follicles are important for various biological functions, including thermoregulation, sensory perception, and social communication. They also play a role in wound healing and can serve as a source of stem cells that can differentiate into other cell types.

Medically, hair is defined as a threadlike structure that grows from the follicles found in the skin of mammals. It is primarily made up of a protein called keratin and consists of three parts: the medulla (the innermost part or core), the cortex (middle layer containing keratin filaments) and the cuticle (outer layer of overlapping scales).

Hair growth occurs in cycles, with each cycle consisting of a growth phase (anagen), a transitional phase (catagen), and a resting phase (telogen). The length of hair is determined by the duration of the anagen phase.

While hair plays a crucial role in protecting the skin from external factors like UV radiation, temperature changes, and physical damage, it also serves as an essential aspect of human aesthetics and identity.

Minoxidil is a medication that is primarily used to treat hair loss. It is a vasodilator, which means it widens blood vessels and improves blood flow. When applied to the scalp, it helps to stimulate hair growth and slows down hair loss. It is available in topical form as a solution or foam, and is usually applied once or twice a day. Minoxidil is not intended for use in children, and women who are pregnant or breastfeeding should consult with their doctor before using it.

It's important to note that minoxidil does not work for everyone, and it may take several months of regular use before any new hair growth is seen. Additionally, if the medication is discontinued, any hair gained during treatment will likely be lost over time. Common side effects of minoxidil include scalp irritation, unwanted hair growth on other parts of the body, and changes in the color or texture of existing hair. It's important to follow the instructions provided by a healthcare professional when using minoxidil.

Scalp dermatoses refer to various skin conditions that affect the scalp. These can include inflammatory conditions such as seborrheic dermatitis (dandruff, cradle cap), psoriasis, atopic dermatitis (eczema), and lichen planus; infectious processes like bacterial folliculitis, tinea capitis (ringworm of the scalp), and viral infections; as well as autoimmune conditions such as alopecia areata. Symptoms can range from mild scaling and itching to severe redness, pain, and hair loss. The specific diagnosis and treatment of scalp dermatoses depend on the underlying cause.

Folliculitis is a medical condition characterized by inflammation of one or more hair follicles, typically appearing as small red bumps or pimples that surround the affected follicle. It can occur anywhere on the body where hair grows, but it's most common in areas exposed to friction, heat, and tight clothing such as the neck, back, legs, arms, and buttocks.

Folliculitis can be caused by various factors, including bacterial or fungal infections, irritation from shaving or waxing, ingrown hairs, and exposure to chemicals or sweat. The severity of folliculitis ranges from mild cases that resolve on their own within a few days to severe cases that may require medical treatment.

Treatment for folliculitis depends on the underlying cause. For bacterial infections, antibiotics may be prescribed, while antifungal medications are used for fungal infections. In some cases, topical treatments such as creams or gels may be sufficient to treat mild folliculitis, while more severe cases may require oral medication or other medical interventions.

Dermoscopy, also known as dermatoscopy or epiluminescence microscopy, is a non-invasive diagnostic technique used in dermatology to evaluate skin lesions, such as moles and pigmented skin tumors. This method involves the use of a handheld device called a dermoscope, which consists of a magnifying lens, a light source, and a transparent plate or immersion fluid that allows for better visualization of the skin's surface structures.

Dermoscopy enables dermatologists to examine the pigmented patterns, vascular structures, and other morphological features hidden beneath the skin's surface that are not visible to the naked eye. By observing these details, dermatologists can improve their ability to differentiate between benign and malignant lesions, leading to more accurate diagnoses and appropriate treatment decisions.

The primary uses of dermoscopy include:

1. Early detection and diagnosis of melanoma and other skin cancers, such as basal cell carcinoma and squamous cell carcinoma.
2. Monitoring the evolution of suspicious moles or lesions over time.
3. Assisting in the identification of various benign skin growths, like seborrheic keratoses, dermatofibromas, and nevi (moles).
4. Improving the diagnostic accuracy for infectious skin conditions, inflammatory processes, and other dermatological disorders.

Overall, dermoscopy is a valuable tool in the field of dermatology that enhances the clinician's ability to diagnose and manage various skin conditions accurately and effectively.

Tinea capitis is a dermatophyte infection, primarily affecting the scalp and hair. It is commonly known as "ringworm of the scalp." The term "ringworm" is a misnomer because it has nothing to do with worms; instead, it refers to the ring-like appearance of the rash caused by these fungi.

The infection is more prevalent in children than adults and can spread through direct contact with an infected person or animal (like pets), or via contaminated objects such as combs, brushes, hats, etc. The causative agents are typically mold-like fungi called dermatophytes, which belong to the genera Microsporum or Trichophyton.

Symptoms of tinea capitis include itchiness, scaling, hair loss (in patches), and the presence of black dots on the scalp where broken hairs remain. In some cases, inflammation and pustules may occur. Diagnosis is usually confirmed through microscopic examination of hair or scale samples, and sometimes by culture.

Treatment typically involves oral antifungal medications like griseofulvin, terbinafine, itraconazole, or fluconazole for several weeks to ensure complete eradication of the fungus. Topical antifungals are often used in conjunction with oral therapy. Good hygiene practices and avoiding sharing personal items can help prevent transmission.

Trichotillomania is defined as an irresistible urge or impulse to pull out one's hair from the scalp, eyebrows, eyelashes, or other areas of the body, resulting in noticeable hair loss. It is a mental disorder that falls under the category of obsessive-compulsive and related disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

People with trichotillomania may experience increasing tension or anxiety before pulling their hair, and they often feel relief or pleasure after doing so. The behavior can occur during periods of stress or as a way to cope with negative emotions, but it can also happen without the individual being fully aware of it.

In addition to hair loss, trichotillomania can cause significant distress and impairment in social, occupational, or other areas of functioning. Treatment typically involves cognitive-behavioral therapy (CBT) and medication, such as selective serotonin reuptake inhibitors (SSRIs).

A cicatrix is a medical term that refers to a scar or the process of scar formation. It is the result of the healing process following damage to body tissues, such as from an injury, wound, or surgery. During the healing process, specialized cells called fibroblasts produce collagen, which helps to reconnect and strengthen the damaged tissue. The resulting scar tissue may have a different texture, color, or appearance compared to the surrounding healthy tissue.

Cicatrix formation is a natural part of the body's healing response, but excessive scarring can sometimes cause functional impairment, pain, or cosmetic concerns. In such cases, various treatments may be used to minimize or improve the appearance of scars, including topical creams, steroid injections, laser therapy, and surgical revision.

Photophobia is a condition characterized by an abnormal sensitivity to light. It's not a fear of light, despite the name suggesting otherwise. Instead, it refers to the discomfort or pain felt in the eyes due to exposure to light, often leading to a strong desire to avoid light. This can include both natural and artificial light sources.

The severity of photophobia can vary greatly among individuals. Some people may only experience mild discomfort in bright light conditions, while others may find even moderate levels of light intolerable. It can be a symptom of various underlying health issues, including eye diseases or disorders like uveitis, keratitis, corneal abrasions, or optic neuritis, as well as systemic conditions such as migraines, meningitis, or certain medications that increase light sensitivity.

Lichen Planus is a chronic, autoimmune skin condition that can also affect the mucous membranes inside the mouth, genitals, and eyes. It is characterized by the appearance of purplish, flat-topped bumps or lesions on the skin, which may be itchy. The exact cause of Lichen Planus is unknown, but it is believed to occur when the immune system mistakenly attacks cells in the skin or mucous membranes. Certain medications, viral infections, and genetic factors may increase the risk of developing this condition. Treatment typically focuses on managing symptoms and may include topical corticosteroids, oral medications, or light therapy.

The eyebrows are a set of hairs that grow above the eyes on the forehead. They are an important feature of human facial anatomy, and play several roles in non-verbal communication and self-expression. Eyebrows help to prevent sweat and other moisture from dripping into the eyes, and also serve as a protective barrier against dirt, dust, and other foreign particles that might otherwise irritate or damage the eyes.

In addition, eyebrows play an important role in human social interaction and communication. They can convey a range of emotions and facial expressions, such as surprise, anger, fear, happiness, and sadness. Eyebrows can also help to frame the eyes and enhance their appearance, making them an important aspect of personal grooming and beauty.

The eyebrows are made up of several components, including hair follicles, sebaceous glands, and muscles that control their movement. The hairs themselves are composed of a protein called keratin, which also makes up the hair on the head, as well as nails and skin. The color and thickness of eyebrow hair can vary widely from person to person, and may be influenced by factors such as age, genetics, and hormonal changes.

In medical terms, changes in the appearance or condition of the eyebrows can sometimes be a sign of underlying health issues. For example, thinning or loss of eyebrows can be associated with conditions such as alopecia, thyroid disorders, or nutritional deficiencies. Changes in eyebrow shape or position can also be a symptom of certain neurological conditions, such as Bell's palsy or stroke. As such, any significant changes in the appearance or condition of the eyebrows should be evaluated by a healthcare professional to rule out any underlying medical causes.

Triethylenephosphoramide (TEPA) is an alkylating antineoplastic agent, which means it works by preventing the growth of cancer cells. It is used in the treatment of various types of cancers such as Hodgkin's lymphoma and malignant melanoma. TEPA is administered intravenously or intramuscularly and its use is often associated with side effects like nausea, vomiting, and hair loss. It is important to note that this medication should be used under the supervision of a healthcare professional as it can have serious side effects and toxicities.

Hypotrichosis is a medical term that refers to a condition characterized by an abnormal lack or sparseness of hair growth. This can apply to the eyebrows, eyelashes, or scalp hair. It's important to note that this is not a complete loss of hair, but rather a significant reduction in hair density. The onset and severity can vary greatly, and it can be inherited or acquired later in life due to various factors such as diseases, burns, or certain medications.

In medical terms, the skin is the largest organ of the human body. It consists of two main layers: the epidermis (outer layer) and dermis (inner layer), as well as accessory structures like hair follicles, sweat glands, and oil glands. The skin plays a crucial role in protecting us from external factors such as bacteria, viruses, and environmental hazards, while also regulating body temperature and enabling the sense of touch.

Ichthyosis is a group of skin disorders that are characterized by dry, thickened, scaly skin. The name "ichthyosis" comes from the Greek word "ichthys," which means fish, as the skin can have a fish-like scale appearance. These conditions can be inherited or acquired and vary in severity.

The medical definition of ichthyosis is a heterogeneous group of genetic keratinization disorders that result in dry, thickened, and scaly skin. The condition may affect any part of the body, but it most commonly appears on the extremities, scalp, and trunk. Ichthyosis can also have associated symptoms such as redness, itching, and blistering.

The severity of ichthyosis can range from mild to severe, and some forms of the condition may be life-threatening in infancy. The exact symptoms and their severity depend on the specific type of ichthyosis a person has. Treatment for ichthyosis typically involves moisturizing the skin, avoiding irritants, and using medications to help control scaling and inflammation.

Sebaceous glands are microscopic, exocrine glands that are found in the dermis of mammalian skin. They are attached to hair follicles and produce an oily substance called sebum, which is composed of triglycerides, wax esters, squalene, and metabolites of fat-producing cells (fatty acids, cholesterol). Sebum is released through a duct onto the surface of the skin, where it forms a protective barrier that helps to prevent water loss, keeps the skin and hair moisturized, and has antibacterial properties.

Sebaceous glands are distributed throughout the body, but they are most numerous on the face, scalp, and upper trunk. They can also be found in other areas of the body such as the eyelids (where they are known as meibomian glands), the external ear canal, and the genital area.

Abnormalities in sebaceous gland function can lead to various skin conditions, including acne, seborrheic dermatitis, and certain types of skin cancer.

No FAQ available that match "alopecia"

No images available that match "alopecia"